Shares of Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) were down 53.7% during trading on Tuesday . The stock traded as low as $4.12 and last traded at $4.12. Approximately 441 shares changed hands during mid-day trading, a decline of 100% from the average daily volume of 11,821,764 shares. The stock had previously closed at $8.89.
Propanc Biopharma Stock Down 53.7 %
The company’s 50 day simple moving average is $3.65 and its 200 day simple moving average is $1.29.
About Propanc Biopharma
Propanc Biopharma, Inc, a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes.
See Also
- Five stocks we like better than Propanc Biopharma
- What is the FTSE 100 index?
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- What Are Treasury Bonds?
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- 10 Best Airline Stocks to Buy
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
